Uses of Radiopharmaceuticals in Nuclear Medicine

  • Gopal B. Saha


In previous chapters, we described various characteristics and production of radionuclides, preparation of different radiopharmaceuticals using various radionuclides, and their quality control. In the present chapter we shall discuss clinical applications of these radiopharmaceuticals in the diagnosis of various diseases in humans. The discussion is primarily divided into sections on different human organs. In each section the anatomic structure and physiologic function of the organ are briefly described and appropriate nuclear medicine tests are discussed along with their clinical usefulness, particularly with respect to the radiopharmaceuticals used, their pharmacologic aspect, the mechanism of their localization, and diagnosis of various diseases.


Myocardial Perfusion Imaging Gamma Camera Polycythemia Vera Blood Clearance Myocardial Uptake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Suggested Reading

  1. Anghileri LJ, ed. General Processes of Radiotracer Localization. Boca Raton, Fla: CRC Press; 1982.Google Scholar
  2. Anthony CP, Thibodeau GA. Textbook of Anatomy and Physiology. St Louis: Mosby; 1979.Google Scholar
  3. Arnold RW, Subramanian G, McAfee JG, et al. Comparison of 99mTc complexes for renal imaging. J Nucl Med. 1975; 16 : 357.PubMedGoogle Scholar
  4. Atkins HL, Budinger TF, Lebowitz E, et al. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J Nucl Med. 1977; 18 : 133.PubMedGoogle Scholar
  5. Bernier DR, Lang JK, Wells LD. Nuclear Medicine Technology and Techniques. St Louis: Mosby; 1981.Google Scholar
  6. Bland WH, ed. Nuclear Medicine. 2nd ed. New York: McGraw-Hill; 1972.Google Scholar
  7. Colombetti LG, ed. Principles of Radiopharmacology. Boca Raton, Fla: CRC Press; 1979; I-III.Google Scholar
  8. Dilsizian V, Rocco TP, Freedman NMT, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium and stress-redistribution imaging. N Engl J Med. 1990; 323 : 141.PubMedCrossRefGoogle Scholar
  9. Early PJ, Sodee DB, eds. Principles and Practice of Nuclear Medicine. St. Louis: Mosby; 1985.Google Scholar
  10. Freeman LM, ed. Freeman and Johnson’s Clinical Radionuclide Imaging. 3rd ed. New York: Grune & Stratton; 1984.Google Scholar
  11. Gallagher BM, Anasri A, Atkins H, et al. Radiopharmaceuticals XXVII. 18Flabeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977; 18 : 990.PubMedGoogle Scholar
  12. Gould KL. Myocardial metabolism by positron emission tomography in hypertropic cardiomyopathy. J Am Coll Cardiol. 1989; 13 : 325.PubMedCrossRefGoogle Scholar
  13. Greenfield LD, Uszler JM. Nuclear medicine in clinical practice. Deerfield Beach, Fla: Verlag Chemie International; 1982.Google Scholar
  14. Harbert J, Rocha AFG, eds. Textbook of Nuclear Medicine, Vol II: Clinical Applications. Philadelphia: Lea & Febiger; 1984.Google Scholar
  15. Hauser W, Atkins HL, Nelson KG, et al. Technetium-99m-DTPA: a new radiopharmaceutical for brain and kidney imaging. Radiology. 1970; 94 : 679.PubMedGoogle Scholar
  16. Hladik WB, III, Ponto JA, Lentle BC, et al. Iatrogenic alterations in the biodistribution of radiotracers as a result of drug therapy: reported instances. In: Hladik WB, III, Saha GB, Study KT, eds. Essentials of Nuclear Medicine Science. Baltimore, Md: Williams and Wilkins; 1987; 189.Google Scholar
  17. Johnson LL, Seldin DW. Clinical experience with technetium-99m Teboroxime, a neutral, lipophilic myocardial perfusion imaging agent. Am J Cardiol. 1990; 66 : 63E.CrossRefGoogle Scholar
  18. Keyes JW, Jr. Manual of Nuclear Medicine Procedures. 3rd ed. Boca Raton, Fla: CRC Press; 1978.Google Scholar
  19. Khaw BA, Gold HK, Yasuda T, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin specific antibody. Circulation. 1986; 74 : 501.PubMedCrossRefGoogle Scholar
  20. Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial T1–201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol. 1988; 12(6) :1456.PubMedCrossRefGoogle Scholar
  21. Kuhl DE, Barrio JR, Huang SC, et al. Quantifying local cerebral blood flow by N-isopropyl-p-123I-iodoamphetamine (IMP) tomography. J Nucl Med. 1982; 236:196.Google Scholar
  22. Leveille J, Demonceau G, De Roo M, et al. Characterization of technetium-99mL,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans. J Nucl Med. 1989; 30 : 1902.PubMedGoogle Scholar
  23. Maisey MN, Britton KE, Gilday D, eds. Clinical Nuclear Medicine. London: Chapman and Hall; 1983.Google Scholar
  24. McAfee JG, Grossman ZD, Gagne G, et al. Comparison of renal extraction efficiencies for radioactive agents in the normal dog. J Nucl Med. 1981; 22 : 333.PubMedGoogle Scholar
  25. Mettler FA, Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging. 3rd ed. New York: Grune & Stratton; 1991.Google Scholar
  26. Narra RK, Nunn AD, Kuczynski, et al. A neutral technetium-99m complex for myocardial imaging. J Nucl Med. 1989; 30 : 1830.PubMedGoogle Scholar
  27. Phelps ME, Hoffman EJ, Selin C, et al. Investigation of F-18-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978; 19 : 1311.PubMedGoogle Scholar
  28. Saha GB, Go RT, Maclntyre WJ, et al. Use of 82Sr/82Rb generator in clinical PET studies. Nucl Med Biol. 1990; 17 : 763.Google Scholar
  29. Sapirstein LA, Vigt DG, Mandel MJ, et al. Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol. 1955; 181 : 330.PubMedGoogle Scholar
  30. Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981; 63 : 1259.PubMedCrossRefGoogle Scholar
  31. Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HMPAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med. 1986; 27 : 171.PubMedGoogle Scholar
  32. Soin JS, Brooks HL, eds. Nuclear Cardiology for Clinicians. New York: Futura; 1980.Google Scholar
  33. Subramanian G, McAfee JG, Blair RJ, et al. Technetium 99m methylene diphosphonate—a superior agent for skeletal imaging; comparison with other technetium complexes. J Nucl Med. 1975; 16 : 744.PubMedGoogle Scholar
  34. Taylor A, Jr, Eshima D, Fritzberg AR, et al. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986; 27 : 795.PubMedGoogle Scholar
  35. Taylor A, Jr, Eshima D, Christian PE, et al. Technetium-99m kit formulation: preliminary results in normal volunteers and patients with renal failure. J Nucl Med. 1988; 29 616.PubMedGoogle Scholar
  36. Vallabhajoshula S, Zimmerman RE, Pickard M, et al. Technetium-99m ECD: a new brain imaging agent. In vivo kinetics and biodistribution studies in normal human studies. J Nucl Med. 1989; 30 : 599.Google Scholar
  37. Wackers FJT, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30: 301.PubMedGoogle Scholar
  38. Wistow BW, Subramaniam G, Gagne GM, et al. Experimental and clinical trials of new 99mTc-labeled hepatobiliary agents. Radiology. 1978; 128 : 793.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Gopal B. Saha
    • 1
  1. 1.Department of Nuclear MedicineThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations